27 November 2010 in Transplantation
This study assessed the capacity of alginate-encapsulated islets to reverse diabetes in a pig-to-primate model. Adult pig islets were encapsulated in microcapsules implanted under the kidney capsule (n=4) or in a subcutaneous macrodevice (n=5) in diabetic primates. Fasting blood glucose (FBG), insulin, porcine C-peptide, glycosylated hemoglobin (HbA1C), and cellular and humoral responses were followed. Nonencapsulated pig islets were rejected within 7 days. A transient decrease of FBG was observed only during the 2 weeks after microencapsulated pig islet implantation under the kidney capsule. After subcutaneous transplantation of a macrodevice, diabetes was corrected up to a maximum of 6 months in five animals: FBG less than 107 mg/dL and HbA1C at 8%±1.4%. Two of the five animals received a new macrodevice between 25 and 35 weeks after the first graft dysfunction (HbA1C ≥13), and diabetes was controlled for an additional 18 weeks in these animals. Although a strong humoral response was elicited after transplantation of encapsulated islets, a total impermeability of alginate 3% wt/vol to IgG was demonstrated before and up to 20 weeks after transplantation of the subcutaneous macrodevice. Pig islets encapsulated in a subcutaneous macrodevice can control diabetes up to 6 months without immunosuppression.
27 March 2007 in Transplantation
In vitro, mesenchymal stem cells (MSCs) have demonstrated a low immunogenic profile. In this study, we tested the immune response to allogeneic MSCs in immunocompetent swines both in vitro and in vivo. Major histocompatibility complex–controlled swine leukocyte antigen (SLA)cd and SLAdd were used as donor and recipient, respectively. In vitro, proliferative responses were tested by mixed lymphocyte reaction (MLR) or cocultures and cytokine profiling by enzyme-linked immunosorbent assay. In vivo, allogeneic MSCs were injected in cardiac infarcted area (n=3) and compared with subcutaneous injections of either MSCs (n=2) or peripheral blood mononuclear cells (PBMCs; n=2). Two additional animals received a skin graft as controls. No immunosuppression was used. Specific antidonor humoral responses were tested by flow cytometry and complement-dependent cytotoxicity assay. In vitro, either unstimulated MSCs or interferon (IFN)-γ stimulated MSC failed to elicit a proliferative response (stimulation index: 1.23 vs. 1.12 vs. 36.9 for controls, P<.001). Concomitantly to the absence of proliferation to MSCs, low production of IFN-γ and interleukin-2 was evidenced in supernatants while the production of Th2 cytokines was comparable to controls. In vivo, all animals receiving skin grafts, subcutaneous PBMCs and intracardiac MSCs injections developed donor-specific cellular and humoral responses (immunoglobulins M and G) with antibody-complement-mediated cytotoxicity. Subcutaneous MSCs injection needed a rechallenge to similarly develop a cytotoxic humoral response. Intracardiac allogeneic porcine mesenchymal stem cells elicit an immune response despite their low immunogenic profile in vitro. This result suggests that in vivo characteristics of allogeneic MSCs might differ and emphasizes the importance of pursuing research both in vitro and in vivo.
15 May 2006 in Transplantation
Pig islets xenotransplantation remains associated with a strong humoral and cellular xenogeneic immune responses. The aim of this study was to assess the long-term biocompatibility of alginate encapsulated pig islets after transplantation in primates. Adult pig islets encapsulated in alginate under optimal conditions (n=7) or not (n=5) were transplanted under the kidney capsule of nondiabetic Cynomolgus maccacus. Additional primates received empty capsules (n=1) and nonencapsulated pig islets (n=2) as controls. Capsule integrity, cellular overgrowth, pig islet survival, porcine C-peptide and anti-pig IgM/IgG antibodies were examined up to 6 months after implantation. Nonencapsulated islets and islets encapsulated in nonoptimal capsules were rapidly destroyed. In seven primates receiving perfectly encapsulated pig islets, part of the islets survived up to 6 months after implantation without immunosuppression. Porcine C-peptide was detected after 1 month in 71% of the animals. The majority of grafts (86%) were intact and completely free of cellular overgrowth or capsule fibrosis. Explanted capsules, after 135 (n=2/2) and 180 (n=2/3) days, demonstrated residual insulin content and responses to glucose challenge (stimulation index of 2.2). Partial islet survival was obtained despite an elicited anti-pig IgG humoral response. Optimal alginate encapsulation significantly prolonged adult pig islet survival into primates for up to 6 months, even in the presence of antibody response.
27 January 1998 in Transplantation
Background. Natural antibodies (NAbs) against a terminal α1-3 galactosyl(αGal) epitope have been identified as the major human anti-pig NAbs. Methods and Results. We used two synthetic αGal trisaccharides-type 6 (αGal6) and type 2(αGal2)-linked to an inert matrix to remove NAbs from human plasma in vitro. Flow cytometry indicated that an average of 85% of the NAb binding activity was depleted by adsorption with αGal6. By measuring the binding of NAbs to pig peripheral blood mononuclear cells and bone marrow cells, we demonstrated that αGal6 was more effective than αGal2 in removing NAbs, and the combination of αGal6 + αGal2 did not further increase removal of NAbs. The specificity of the removal of NAbs (IgM and IgG) reactive with the αGal epitope by αGal6 matrix was shown by enzyme-linked immunosorbent assay. In vivo studies in nonhuman primates compared plasma perfusion through a αGal6 immunoaffinity column with hemoperfusion through a pig liver for changes in blood pressure, hematocrit, platelets, and NAb adsorption. Conclusions. Both methods reduced the level of anti-pig IgM and IgG xenoreactive antibodies to nearly background, but column perfusion caused less hypotension and reduction in platelets than liver perfusion. Four pig kidneys transplanted into monkeys after column perfusion did not undergo hyperacute rejection, remaining functional for 2-10 days, with a mean functional period of 7 days, demonstrating that a pig kidney can support renal function in a primate.
1 April 1984 in Annals of Surgery
From an institutional review of 103 pancreaticoduodenal resections (PDRs) performed during the period 1968–1981, risk factors and selection criteria of this procedure were evaluated. A total of 43.7% of the patients were operated on for benign lesions, mainly right-sided chronic pancreatitis (35%); 56.3% of the interventions were performed for malignant disease, mainly carcinoma of the periampullary region. Despite the absence of any selection, the hospital mortality in 103 consecutive PDRs only reached 10.6% for the whole group (11/103 patients) and 8.3% for the elective group (8/96 patients). Mortality was significantly influenced by age barrier over 65 years (p < 0.0001) and by urgent degree of surgery (p < 0.03). All three patients with renal insufficiency had a fatal outcome after PDR. A total of 19.4% of the patients (20/103 patients) developed a surgical complication. The most important complication was pancreatic fistula (15/103 patients, 14.5%) responsible for all digestive-related fatal outcomes (six patients). Surgical treatment of pancreatic fistula (10 patients) is compromised by a high morbidity and a high mortality rate (50%). Postoperative morbidity as well as the incidence of the pancreatic fistula were significantly influenced by the age of the patients over 65 years (p < 0.01 and < 0.001, respectively),'and by the serum bilirubin level over 6 mg/dl (p < 0.002). The poor quality of the pancreatic tissue (p < 0.03) and the urgent degree of the intervention (p < 0.03) also raised the incidence of pancreatic leakage. Morbidity rate was more important in the malignant disease group (p < 0.05). Corrected 5-year actuarial survival after PDR is excellent for ampullary cancer, moderate for chronic pancreatitis, and extremely poor for pancreatic and bile duct carcinoma. The decision to perform PDR should be taken after evaluation of the aforementioned risk factors: the emergency, age, serum bilirubin, quality of pancreatic tissue and renal insufficiency, underlying disease, and psycho-social status of the patient.
23 February 2016 in Interactive CardioVascular and Thoracic Surgery
Extracellular matrix (ECM) derived from small intestinal submucosa (SIS) is widely used in clinical applications as a scaffold for tissue repair. Recently, CorMatrix® porcine SIS-ECM (CorMatrix Cardiovascular, Inc., Roswell, GA, USA) has gained popularity for ‘next-generation’ cardiovascular tissue engineering due to its ease of use, remodelling properties, lack of immunogenicity, absorbability and potential to promote native tissue growth. Here, we provide an overview of the biology of porcine SIS-ECM and systematically review the preclinical and clinical literature on its use in cardiovascular surgery. CorMatrix® has been used in a variety of cardiovascular surgical applications, and since it is the most widely used SIS-ECM, this material is the focus of this review. Since CorMatrix® is a relatively new product for cardiovascular surgery, some clinical and preclinical studies published lack systematic reporting of functional and pathological findings in sufficient numbers of subjects. There are also emerging reports to suggest that, contrary to expectations, an undesirable inflammatory response may occur in CorMatrix® implants in humans and longer-term outcomes at particular sites, such as the heart valves, may be suboptimal. Large-scale clinical studies are needed driven by robust protocols that aim to quantify the pathological process of tissue repair.